Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections.
Open accessThe DOI matches its Crossref record; 695 of the 697 references it cites were found in a registry or an index.
Abstract
Background: The Infectious Diseases Society of America is committed to providing up-to-date guidance on the treatment of antimicrobial-resistant infections. This guidance document focuses on infections caused by extended-spectrum β-lactamase–producing Enterobacterales, AmpC β-lactamase-producing Enterobacterales, carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa with difficult-to-treat resistance, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia. This updated document replaces previous versions of the guidance document. Methods: A panel of 6 infectious diseases specialists with expertise in managing antimicrobial-resistant infections formulated questions about the treatment of infections caused by extended-spectrum β-lactamase-producing Enterobacterales, AmpC β-lactamase-producing Enterobacterales, carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa with difficult-to-treat resistance, carbapenem-resistant Acinetobacter baumannii, and S. maltophilia. Because of differences in the epidemiology of resistance and availability of specific anti-infectives internationally, this document focuses on the treatment of infections in the United States. Results: Preferred and alternative suggested treatment approaches are provided with accompanying rationales, assuming the causative organism has been identified and antibiotic susceptibility results are known. Approaches to empiric treatment, transitioning to oral therapy, duration of therapy, and other management considerations are also discussed briefly. Suggested approaches apply for both adult and pediatric populations, although suggested antibiotic dosages are provided only for adults. Conclusions: The field of antimicrobial-resistance is highly dynamic. Consultation with an infectious diseases specialist is recommended for the treatment of antimicrobial resistant infections. This document is current as of 31 December 2022 and will be updated periodically. The most current version of this document, including date of publication, is available at www.idsociety.org/practice-guideline/amr-guidance/.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Items 601–695 of 695
Carbapenem Susceptibility Discords among Acinetobacter Isolates
Jones, R., Sader, H. S., Fritsche, T. R., & Rhomberg, P. R. (2005) · Clinical Infectious Diseases · doi:10.1086/498754 · Cited by 26
Sénard, O., Lafaurie, M., Lesprit, P., Nguyen, Y., Lescure, F.-X., Therby, A., Fihman, V., Oubaya, N., & Lepeule, R. (2019) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-019-03701-0 · Cited by 26
Castanheira, M., Sader, H. S., Mendes, R. E., & Jones, R. N. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02418-19 · Cited by 26
Lasko, M. J., Gethers, M. L., Tabor-Rennie, J. L., Nicolau, D. P., & Kuti, J. L. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02167-21 · Cited by 26
Gaibani, P., Amadesi, S., Lazzarotto, T., & Ambretti, S. (2022) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2022.06.021 · Cited by 26
Lima, O., Sousa, A., Longueira-Suárez, R., Filgueira, A., Taboada-Martínez, C., Portela-Pino, C., Nodar, A., Vidal, F. J. V., Martínez-Lamas, L., Pérez‐Landeiro, A., et al. (2022) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-022-04482-9 · Cited by 26
Lodise, T. P., O’Donnell, J. N., Raja, S. M., Guptill, J. T., Zaharoff, S., Schwager, N., Fowler, V. G., Beresnev, T. H., Wall, A., Wiegand, K., et al. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00935-22 · Cited by 26
Clinical outcomes using minocycline for Stenotrophomonas maltophilia infections
Jacobson, S., Noa, L. J., Wallace, M. R., & Bowman, M. C. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw327 · Cited by 25
Zhou, M., Yang, Q., Lomovskaya, O., Sun, D., Kudinha, T., Xu, Z., Zhang, G., Chen, X., & Xu, Y. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky251 · Cited by 25
Biagi, M. J., Butler, D. A., Tan, X., Qasmieh, S., & Wenzler, E. (2019) · Antibiotics · doi:10.3390/antibiotics8010027 · Cited by 25
Phillips, M. C., Wald‐Dickler, N., Loomis, K. J., Luna, B. M., & Spellberg, B. J. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa460 · Cited by 25
Karaba, S. M., Goodman, K. E., Amoah, J., Cosgrove, S. E., & Tamma, P. D. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00793-21 · Cited by 25
Self-citationWang, C.-C., Chao, T.-Y., Chen, Y., Fang, W., Kao, H., Chen, H., Tsai, Y.-C., Shen, L.-S., Li, C.-L., Chang, H., et al. (2014) · Biomedical Journal · doi:10.4103/2319-4170.132879 · Cited by 24
Taşbakan, M. S., Pullukçu, H., Sipahf, O., Taşbakan, M., Aydemir, Ş., & Bacakoğlu, F. (2011) · Journal of Chemotherapy · doi:10.1179/joc.2011.23.6.345 · Cited by 24
Dizbay, M., Özger, H. S., Karaşahin, Ö., & Karaşahin, E. F. (2016) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-1506-157 · Cited by 24
Fox, M. T., Melia, M. T., Same, R. G., Conley, A. T., & Tamma, P. D. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.01.025 · Cited by 24
Self-citationRobin, F., Auzou, M., Bonnet, R., Lebreuilly, R., Isnard, C., Cattoir, V., & Guérin, F. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00675-18 · Cited by 24
In vitro activity of omadacycline against pathogens isolated from Mainland China during 2017–2018
Dong, D., Zheng, Y., Chen, Q., Guo, Y. P., Yang, Y., Wu, S., Zhu, D., Deng, D., Bradford, P. A., Reinhart, H. H., et al. (2020) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-020-03877-w · Cited by 24
Lodise, T. P., O’Donnell, J. N., Balevic, S. J., Liu, X., Gu, K., George, J. M., Raja, S. M., Guptill, J. T., Zaharoff, S., Schwager, N., et al. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00936-22 · Cited by 24
Pfaller, M. A., Shortridge, D., Sader, H. S., Flamm, R. K., & Castanheira, M. (2017) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2017.05.025 · Cited by 23
Karlowsky, J. A., Lob, S. H., Young, K., Motyl, M. R., & Sahm, D. F. (2019) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2019.05.001 · Cited by 23
Johnston, B., THURAS, P. D., Porter, S. B., Anacker, M. L., VonBank, B., Vagnone, P. S., Witwer, M. L., Castanheira, M., & Johnson, J. R. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02408-19 · Cited by 23
Qin, J., Huang, H., Zhou, H., Zhu, Y., Xu, Y., & Du, B. (2021) · Scientific Reports · doi:10.1038/s41598-021-86342-8 · Cited by 23
Zha, L., Zhang, D., Pan, L., Ren, Z., Li, X., Zou, Y., Li, S., Luo, S., Yang, G., & Tefsen, B. (2021) · Infectious Diseases and Therapy · doi:10.1007/s40121-021-00516-5 · Cited by 23
Characterization of Indole-Positive Proteus mirabilis
Matsen, J. M., Blazevic, D. J., Ryan, J. A., & Ewing, W. H. (1972) · Applied Microbiology · doi:10.1128/am.23.3.592-594.1972 · Cited by 22
Stewart, A. G., Harris, P. N. A., Chatfield, M. D., Littleford, R. C., & Paterson, D. L. (2021) · Trials · doi:10.1186/s13063-021-05206-8 · Cited by 22
Dao, B. D., Barreto, J. N., Wolf, R. C., Dierkhising, R., Plevak, M. F., & Tosh, P. K. (2014) · Current Therapeutic Research · doi:10.1016/j.curtheres.2014.08.003 · Cited by 21
Giamarellos‐Bourboulis, E. J., Karnesis, L., Galani, I., & Giamarellou, H. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.12.3997-3999.2002 · Cited by 21
Smith, K. P., Brennan-Krohn, T., Weir, S. K., & Kirby, J. E. (2016) · Journal of Clinical Microbiology · doi:10.1128/jcm.02128-16 · Cited by 21
Jean, S., Hsieh, T.-C., Lee, W., Hsueh, P., Hsu, C.-W., & Lam, C. (2018) · Medicine · doi:10.1097/md.0000000000012278 · Cited by 21
Kulengowski, B., & Burgess, D. S. (2019) · Pathogens and Disease · doi:10.1093/femspd/ftz040 · Cited by 21
Nasir, N., Ahmed, S., Razi, S., Awan, S., & Mahmood, S. F. (2019) · BMC Research Notes · doi:10.1186/s13104-019-4648-7 · Cited by 21
Karlowsky, J. A., Lob, S. H., Young, K., Motyl, M. R., & Sahm, D. F. (2020) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piaa056 · Cited by 21
Iregui, A., Landman, D., & Quale, J. M. (2020) · Microbial Drug Resistance · doi:10.1089/mdr.2019.0423 · Cited by 21
In vitro pharmacodynamics of omadacycline against Escherichia coli and Acinetobacter baumannii
Noel, A., Attwood, M., Bowker, K. E., & MacGowan, A. P. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa508 · Cited by 21
CON: Testing for ESBL production is unnecessary for ceftriaxone-resistant Enterobacterales
Mathers, A. J., & Lewis, J. S. (2021) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlab020 · Cited by 21
Self-citationZhang, H., Jia, P., Zhu, Y., Zhang, G., Zhang, J., Kang, W., Duan, S., Zhang, W., Yang, Q., & Xu, Y. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s325520 · Cited by 21
Fratoni, A. J., Kuti, J. L., & Nicolau, D. P. (2021) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2021.106395 · Cited by 21
Paterson, D. L., Bassetti, M., Motyl, M. R., Johnson, M. G., Castanheira, M., Jensen, E. H., Huntington, J. A., Yu, B., Wolf, D. J., & Bruno, C. J. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac184 · Cited by 21
Sader, H. S., Castanheira, M., Flamm, R. K., Huband, M. D., & Jones, R. N. (2016) · Surgical Infections · doi:10.1089/sur.2016.036 · Cited by 20
Morrisette, T., Alosaimy, S., Lagnf, A. M., Frens, J. J., Webb, A. J., Veve, M. P., Stevens, R. W., Bouchard, J. L., Gore, T. W., Ansari, I., et al. (2022) · Infectious Diseases and Therapy · doi:10.1007/s40121-022-00645-5 · Cited by 20
The Role of Aerolized Colistin in the Treatment of Hospital-Acquired Pneumonia
Ekren, P. K., Töreyin, Z. N., Sayıner, A., & Bacakoğlu, F. (2016) · Critical Care Medicine · doi:10.1097/ccm.0000000000001539 · Cited by 19
Derrick, C., Bookstaver, P. B., Lu, K., Bland, C. M., King, S. T., Stover, K. R., Rumley, K. F., MacVane, S. H., Swindler, J., Kincaid, S. E., et al. (2020) · Antibiotics · doi:10.3390/antibiotics9050254 · Cited by 19
Karlowsky, J. A., Walkty, A. J., Baxter, M. R., Adam, H. J., Lagacé-Wiens, P. R. S., Schweizer, F., Bay, D. C., Lynch, J. P., Mulvey, M. R., & Zhanel, G. G. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01724-22 · Cited by 19
Chabert, P., Provoost, J., Cohen, S., Dupieux, C., Bitker, L., Ferry, T., Goutelle, S., & Richard, J. (2022) · Annals of Intensive Care · doi:10.1186/s13613-022-01059-9 · Cited by 19
Dahyot, S., & Mammeri, H. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05630-11 · Cited by 18
Fernández-Cuenca, F., Tomás, M., Caballero-Moyano, F. J., Bou, G., Pascual, Á., Vilanova, A., Benítez, A. B., Montiel, N., Calleja, A. I. L., Guerra, L. O., et al. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx464 · Cited by 18
Sahu, C., Pal, S., Patel, S. S., Singh, S. K., Gurjar, M., & Ghoshal, U. (2020) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2020.1788224 · Cited by 18
Negri, M.-C., & Baquero, F. (1999) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.1999.tb00721.x · Cited by 18
Asempa, T. E., Kois, A. K., Gill, C. M., & Nicolau, D. P. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac425 · Cited by 18
Esterly, J. S., Qi, C., Malczynski, M., & Scheetz, M. H. (2010) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.4.354 · Cited by 17
Baek, J. H., Kim, C. O., Jeong, S. J., Ku, N. S., Han, S. H., Choi, J. Y., Yong, D., Song, Y. G., Lee, K., & Kim, J. M. (2014) · Yonsei Medical Journal · doi:10.3349/ymj.2014.55.4.987 · Cited by 17
Lee, Y., Wang, Y.-C., Kuo, S., Chen, C.-T., Liu, C.-P., Liu, Y.-M., Chen, T.-L., & Yang, Y. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00931-17 · Cited by 17
Akata, K., Muratani, T., Yatera, K., Naito, K., Noguchi, S., Yamasaki, K., Kawanami, T., Kido, T., & Mukae, H. (2019) · PLoS ONE · doi:10.1371/journal.pone.0218589 · Cited by 17
Diarra, A., Pascal, L. B., Carpentier, B., Baclet, N., Cabaret, P., Georgel, A., Dubreuil, L. J., & Weyrich, P. (2021) · Infectious Diseases Now · doi:10.1016/j.idnow.2021.01.014 · Cited by 17
Holger, D. J., Rebold, N., Alosaimy, S., Morrisette, T., Lagnf, A. M., Belza, A. C., Coyne, A. J. K., Ghali, A. E., Veve, M. P., & Rybak, M. J. (2022) · Infectious Diseases and Therapy · doi:10.1007/s40121-022-00687-9 · Cited by 17
Hakeam, H. A., Askar, G., Sulaiman, K. A. A., Mansour, R., AlQahtani, M. M., Abbara, D., Aldhayyan, N., Dyab, N., Afaneh, L., Islami, M., et al. (2022) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2022.08.020 · Cited by 17
Lepeule, R., Leflon‐Guibout, V., Vanjak, D., Zahar, J., Lafaurie, M., Besson, C., & Lefort, A. (2014) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2014.09.004 · Cited by 16
Campbell, J. D., Lewis, J. S., McElmeel, M. L., Fulcher, L. C., & Jorgensen, J. H. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.06248-11 · Cited by 16
Probing the Mechanism of Inactivation of the FOX-4 Cephamycinase by Avibactam
Nukaga, M., Papp‐Wallace, K. M., Hoshino, T., Lefurgy, S. T., Bethel, C. R., Barnes, M. D., Zeiser, E. T., Johnson, J. K., & Bonomo, R. A. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02371-17 · Cited by 16
Self-citationSears, C. L., File, T. M., Alexander, B. D., McQuillen, D. P., MacIntyre, A. T., Allen, U., Colasanti, J. A., Siddiqui, J., Reveles, K. R., Busky, C., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1040 · Cited by 16
Biagi, M. J., Lee, M., Wu, T., Shajee, A., Patel, S., Deshpande, L. M., Mendes, R. E., & Wenzler, E. (2022) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2022.115674 · Cited by 16
Meini, S., Laureano, R., Tascini, C., Arena, F., Fani, L., Frullini, A., Passaleva, M. T., Roberts, A. T., Mannini, D., Sbrana, F., et al. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.10.014 · Cited by 15
Cai, T., Tamanini, I., Mattevi, D., Verze, P., Palmieri, A., MALOSSINI, G., Mirone, V. G., Novelli, A., Tascini, C., & Johansen, T. E. B. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105935 · Cited by 15
Elbaz, M., & Ben‐Ami, R. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa369 · Cited by 15
Caffrey, A. R., Appaneal, H. J., Liao, J. X., Piehl, E. C., Lopes, V., Dillon, R. J., Puzniak, L., & LaPlante, K. L. (2022) · Antibiotics · doi:10.3390/antibiotics11050626 · Cited by 15
Mounier, R., Guen, R. L., Woerther, P., Nacher, M., Bonnefon, C., Mongardon, N., Langeron, O., Levesque, É., Couffin, S., Houcke, S., et al. (2022) · Annals of Intensive Care · doi:10.1186/s13613-022-01079-5 · Cited by 15
Liu, C., Wang, X., Chen, Y., Hao, H., Li, X., Liang, J., Duan, R., Li, C., Zhang, J., Shao, S., et al. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01282 · Cited by 13
Drozdinsky, G., Neuberger, A., Rakedzon, S., Nelgas, O., Cohen, Y., Rudich, N., Mushinsky, L., Ben‐Zvi, H., Paul, M., & Yahav, D. (2020) · Microbial Drug Resistance · doi:10.1089/mdr.2020.0234 · Cited by 13
Gill, C. M., Aktaş, E., Alfouzan, W. A., Bourassa, L. A., Brink, A. J., Burnham, C. D., Cantón, R., Carmeli, Y., Falcone, M., Kiffer, C. R. V., et al. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01204-21 · Cited by 13
Stefano, A. F. D. D., Radicioni, M. M., Morano, F., Gentili, A., Mallat, E., Cuomo, D., Mazzarella, T., & Fonzo, V. D. (2022) · Antibiotics · doi:10.3390/antibiotics11111458 · Cited by 13
Zappulo, E., Grimaldi, F., Paolillo, R., Pinchera, B., Buonomo, A. R., Picardi, M., Catania, M. R., Pane, F., & Gentile, I. (2022) · Annals of Hematology · doi:10.1007/s00277-022-05006-3 · Cited by 13
Eliopoulos, G. M. (1988) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/22.supplement_a.37 · Cited by 12
Zaidenstein, R., Miller, A., Tal-Jasper, R., Ofer-Friedman, H., Sklarz, M. Y., Katz, D. E., Lazarovitch, T., Lephart, P., Mengesha, B., Tzuman, O., et al. (2018) · Microorganisms · doi:10.3390/microorganisms6010009 · Cited by 12
Ferreira, T. D. C., & Martins, I. S. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s312920 · Cited by 12
Longshaw, C. M., ECHOLS, R. M., Henriksen, A. S., Baba, T., Nguyen, S., & Yamano, Y. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01100-22 · Cited by 12
Widmer, A. F., Kern, W. V., Roth, J. A., Dettenkofer, M., Götting, T., Bertz, H., & Theilacker, C. (2019) · Infection · doi:10.1007/s15010-019-01327-0 · Cited by 11
Imoto, W., Kaneko, Y., Yamada, K., Kuwabara, G., Yamairi, K., Shibata, W., Oshima, K., Niki, M., Nakaie, K., Watanabe, T., et al. (2020) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2020.10.024 · Cited by 11
Walkty, A. J., Karlowsky, J. A., Baxter, M. R., Adam, H. J., Golden, A., Lagacé-Wiens, P. R. S., & Zhanel, G. G. (2021) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2021.115418 · Cited by 11
Adámková, V., Mareković, I., Szabó, J., Pojnar, Ł., Billová, S., Herceg, S. H., Kuraieva, A., & Możejko-Pastewka, B. (2022) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-022-04452-1 · Cited by 11
Sader, H. S., Castanheira, M., Jones, R. N., & Flamm, R. K. (2016) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2016.11.019 · Cited by 10
Stewart, A. G., Cottrell, K., Henderson, A., Vemuri, K. R., Bauer, M. J., Paterson, D. L., & Harris, P. N. A. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.00226-21 · Cited by 10
Emergence of Resistance in Klebsiella aerogenes to Piperacillin-Tazobactam and Ceftriaxone
Custodio, M. M., Sanchez, D., Anderson, B., Ryan, K. L., Walraven, C. J., & Mercier, R.-C. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01038-20 · Cited by 9
Wilson, G., Fitzpatrick, M. A., Suda, K. J., Smith, B. M., González, B., Jones, M., Schweizer, M. L., Evans, M. E., & Evans, C. T. (2022) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlac106 · Cited by 9
Mukerji, A. C., Sharma, M., Taneja, O. P., Saxena, S. N., Bhatnagar, R. K., & Ghosh-Ray, B. (2009) · Chemotherapy · doi:10.1159/000220613 · Cited by 8
Viana, G. F., Saalfeld, S. M. D. S., Moreira, R. R. B., Menegucci, T. C., Garcia, L. B., Cardoso, C. L., Carrara-Marroni, F. E., & Tognim, M. C. B. (2013) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2013.07.001 · Cited by 8
An Improved Extended-Spectrum-β-Lactamase Detection Test Utilizing Aztreonam plus Clavulanate
Thomson, G. K., Ayaz, M., Lutes, K., & Thomson, K. S. (2017) · Journal of Clinical Microbiology · doi:10.1128/jcm.01309-17 · Cited by 8
Peters, D. M., Winter, J., Droege, C. A., Ernst, N. E., & Liao, S. (2020) · Hospital Pharmacy · doi:10.1177/0018578720931463 · Cited by 8
Zhang, H. L., Gontjes, K. J., Han, J., Alby, K., Lapp, Z., Snitkin, E. S., Goldstein, E. J. C., Muldoon, S. R., Tolomeo, P., & Lautenbach, E. (2022) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2022.185 · Cited by 8
Lob, S. H., Hackel, M., Young, K., Motyl, M. R., & Sahm, D. F. (2021) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2021.115421 · Cited by 7
Horwich-Scholefield, S., Lloyd, T., Varghese, V., Yette, E., Huang, S., & Pandori, M. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02288-20 · Cited by 7
Fratoni, A. J., Colmerauer, J. L., Linder, K. E., Nicolau, D. P., & Kuti, J. L. (2021) · Journal of Pharmacy Practice · doi:10.1177/08971900211063301 · Cited by 6
Machuca, I., Guzmán-Puche, J., Pérez‐Nadales, E., Gracia-Ahufinger, I., Mendez, A., Cano, Á., Castón, J. J., Domínguez, A., Torre‐Cisneros, J., & Martínez-Martínez, L. (2022) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2022.07.017 · Cited by 6
Minocycline in the Treatment of Carbapenem-Resistant Klebsiella pneumoniae
Khatri, A. M., Lobo, S. A., Nog, R., Lee, L., Wang, G., & Dhand, A. (2017) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofx163.221 · Cited by 5
Talan, D. A., Stamm, W. E., Hooton, T. M., Moran, G. J., Burke, T., Iravani, A., Reuning-Scherer, J., & Church, D. A. (2000) · JAMA · doi:10.1001/jama.283.12.1583
Research works printed but not linked: 10
- Clinical and Laboratory Standards Institute, 2023, M100: performance standards for antimicrobial susceptibility testing
- Sharara, 2019, Is piperacillin-tazobactam effective for the treatment of pyelonephritis caused by ESBL-producing organisms?, Clin Infect Dis, 71
- Centers for Disease Control and Prevention, 2015, Facility guidance for control of carbapenem-resistant Enterobacteriaceae (CRE): November 2015 update—CRE toolkit
- Chen, 2022, Efficacy and safety of ceftazidime-avibactam for the treatment of carbapenem-resistant enterobacterales bloodstream infection: a systematic review and meta-analysis, Microbiol Spectr, 10
- Shields, 2017, Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections, Antimicrob Agents Chemother, 61
- Li, 2022, Increased expression and amplification of blaKPC-2 contributes to resistance to ceftazidime/avibactam in a sequence type 11 carbapenem-resistant Klebsiella pneumoniae strain, Microbiol Spectr, 10
- Morrissey, 2020, In vitro activity of eravacycline against gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017, Antimicrob Agents Chemother, 64
- Karlowsky, 2020, In vitro activity of imipenem/relebactam and ceftolozane/tazobactam against clinical isolates of gram-negative bacilli with difficult-to-treat resistance and multidrug-resistant phenotypes—SMART United States 2015–2017, Clin Infect Dis, 72
- Skoglund, 2018, In vivo resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa arising by AmpC- and non-AmpC-mediated pathways, Case Rep Infect Dis, 2018
- Cheah, 2015, New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection, J Antimicrob Chemother, 70, 3291
Cited by
ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics
Miller, W. R., & Arias, C. A. (2024) · Nature Reviews Microbiology · doi:10.1038/s41579-024-01054-w · Cited by 862
“…(for which sulbactam is the active component against A. baumannii PBP3) is the current preferred backbone of therapy, with evidence of improved outcomes when used at a high dose (≥9 g per day of sulbactam) in combination with another active agent in mostly observational studies 180 .”
Pseudomonas aeruginosa: Infections, Animal Modeling, and Therapeutics
Wood, S. J., Kuzel, T. M., & Shafikhani, S. H. (2023) · Cells · doi:10.3390/cells12010199 · Cited by 254
Hypervirulent and carbapenem-resistant Klebsiella pneumoniae: A global public health threat
Lei, T.-Y., Liao, B.-B., Yang, L.-R., Wang, Y., & Chen, X.-B. (2024) · Microbiological Research · doi:10.1016/j.micres.2024.127839 · Cited by 174
Kaye, K. S., Belley, A. C., Barth, P., Lahlou, O., Knechtle, P., Motta, P., & Vélicitat, P. (2022) · JAMA · doi:10.1001/jama.2022.17034 · Cited by 147
Carmeli, Y., Cisneros, J. M., Paul, M., Daikos, G. L., Wang, M., Torre‐Cisneros, J., Singer, G., Titov, I., Gumenchuk, I., Zhao, Y., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(24)00499-7 · Cited by 146
Metadata
- Authors
- Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J.
- Affiliations
- Johns Hopkins University (US)
- University of Michigan (US)
- University Hospitals of Cleveland (US)
- University of Virginia (US)
- Department of Medicine, University of North Carolina School of Medicine , Chapel Hill, North Carolina ,
- University of Pittsburgh (US)
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-07-18
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W4384665204
- Cited by
- 740
- References
- 697
- Citations by year
- 2026: 134 · 2025: 159 · 2024: 335 · 2023: 84
- FWCI
- 60.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- AstraZeneca
- Infectious Diseases Society of America
- Case Western Reserve University
- Medicines Company
- Melinta Therapeutics
- Entasis Therapeutics
- European Society of Clinical Microbiology and Infectious Diseases (ESCMID 2022)
- Universidade Federal do Rio Grande do Sul
- Shionogi
- Basilea Pharmaceutica
- Wockhardt
- National Institutes of Health
- Centers for Disease Control and Prevention
- Allergan
- Topics
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Microbiology (medical) › Infections and bacterial resistance
- Keywords
- antimicrobial resistance, gram-negative bacterial infection, extended-spectrum beta-lactamase, AmpC beta-lactamase, carbapenem-resistant Enterobacteriaceae, Pseudomonas aeruginosa, carbapenem-resistant Acinetobacter baumannii, Stenotrophomonas maltophilia, antimicrobial therapy, empirical treatment, oral therapy, treatment duration, pediatric infection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.